Frost edit · Free shipping over $70 · Cool essentials
glp-1/gip agonist

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

SKU: 25221614637
4.7
USD28.71 USD57.71

Pay in 4 interest-free payments of $7.18 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 22 - Aug 27

Description

3209-A ENGINEERED MESENCHYMAL STEM CELL-DERIVED EXOSOMES PROMOTE MACROPHAGE EFFEROCYTOSIS VIA ADAM9/MERTK AXIS IN ACUTE-ON-CHRONIC LIVER FAILURE Junyi Wang 1 , Zhihui Li 2 , Shibo Meng 3 , Junfeng Chen 1 , Bingliang Lin 3 and Jing Zhang 4 , (1)The Third Affiliated Hospital of Sun Yat-Sen University, (2)Sun Yat-Sen University, (3)The Third Affiliated Hospital, Sun Yat-Sen University, (4)Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University Background: Acute-on-Chronic liver failure is a disease with a high mortality rate, the only cure currently available is liver transplantation.Our previous study showed that intravenous injection of mesenchymal stem cells could improve survival rate of acute-on-chronic liver failure patients, and expressed higher levels of Mertk, which could promote macrophage phagocytosis of apoptotic cells and reduced the occurrence of secondary necrosis in the efferocytosis .Mertk can be cleaved by a cell membrane protein ADAM9 and subsequently loses its biological activity.MiR-126 is an upstream molecule of ADAM9 that can inhibit its generation.In this study,we aim to load miR-126 into exosomes of mesenchymal stem cells by electroporation as engineered exosomes,then apply it to the treatment of acute-on-chronic cell model and explore the mechanism

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

IGF-1 LR3 works like natural IGF-1 binding to the IGF-1 receptor

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

Smoking-induced skeletal muscle dysfunction from evidence to mechanisms

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

J.GostoutB

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

04.25.25 Maryland man filed lawsuit after developing NAION A 62-year-old man who developed NAION and lost vision in both eyes filed a lawsuit against Novo Nordisk

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR

Low glutathione (a powerful antioxidant) can impair the bodys detox pathways, which can contribute to brain and lung inflammation

glp-1/gip agonist GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Amino acid sequence of GLP-1R/GIPR
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products